Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Parallel Group, Multiple Dose, 6-Week Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Asenapine in Elderly Subjects With Psychosis

Next Previous
X
Search
Trial Profile

A Randomized, Parallel Group, Multiple Dose, 6-Week Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Asenapine in Elderly Subjects With Psychosis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 11 Feb 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Asenapine (Primary)
  • Indications Psychotic disorders
  • Focus Adverse reactions; Pharmacokinetics; Registrational
  • Sponsors Merck Sharp & Dohme; Organon; Pfizer

    • Most Recent Events

    • 01 Sep 2010 Results were reported at the 23rd Annual Congress of the European College of Neuropsychopharmacology.
    • 27 May 2010 Tolerability and pharmacokinetic outcomes were reported at the 163rd Annual Meeting of the American Psychiatric Association.
    • 13 Oct 2009 Schering-Plough added instead of Organon as Organon was taken over by Schering-Plough.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top